Immunetrics

	Leadership Immunetrics is staffed by a team of carefully trained Ph.D.-level biologists and mathematical modelers under the leadership of: Steven Chang, M.S., CEO, board member, is a successful technology entrepreneur with more than 18 years of experience in developing complex computer models, optimization algorithms, and data mining systems. He was the founding Chairman of the board of directors for SCAI (Society for Complexity in Acute Illnesses). As founding CEO of Futuristics Labs, Steve raised two rounds of financing totaling over $10 million. Futuristics' proprietary technologies enabled real-time ad hoc query processing on terabyte sized databases with no loss in data resolution. Prior to founding Futuristics, Steve headed up the Intelligent Software Systems group at Westinghouse/CBS Corporation's Science and Technology Center and developed decision optimization and computer modeling systems that were successfully deployed in many Fortune 500 companies, including Kraft Foods, Colgate-Palmolive, Nestle, and Airborne Express. He was also instrumental in establishing the first Westinghouse presence on the Internet and was the recipient of two George Westinghouse Signature Awards for Excellence. Steve attained both BS and MS degrees in Electrical Engineering from the Rensselaer Polytechnic Institute. John Bartels, senior software architect, has been developing mathematical models for 10 years, primarily in biological applications. John provides the technical direction and foundation for Immunetrics' custom simulation platforms and proprietary tools. Prior to joining Immunetrics, John held senior engineering positions at Nomos Corporation, Westinghouse Electric Corporation, and Digital Equipment Corporation. John holds a BS in Computer Science from the Rensselaer Polytechnic Institute. Patricia Rogan, Vice President, Operations, has more than twenty years of experience in executive financial and administrative management at public, private and startup technology companies, including software and biotechnology firms. Prior to joining Immunetrics, Pat was an executive at Innovation Works, Inc., a regional seed stage investor in technology companies. She previously held executive management positions at LaunchCyte, LLC and Dravo Corporation. Pat holds a B.A. and an MBA from the University of Pittsburgh. Timothy R. Billiar, MD , Advisory board member, consultant and co-founder, is the George Vance Foster Professor and Chair of the Department of Surgery at the University of Pittsburgh. Tim received his M.D. degree from the University of Chicago, Pritzker School of Medicine in 1983, and then completed surgical training at the University of Minnesota and the University of Pittsburgh. This included a research fellowship under the guidance of Dr. Richard L. Simmons. Dr. Billiar is a trauma surgeon and critical care physician with a longstanding interest in inflammation and organ dysfunction. His laboratory was the first to clone the human inducible nitric oxide synthase and characterize its expression and function in a number of inflammatory settings. His laboratory also investigates hepatic responses in sepsis, hemorrhagic shock and ischemia reperfusion as well as aspects of acute vascular injury. He is currently funded by two program project grants, two RO1s, and is co-director of a trauma training grant. He is a past president of the Society of University Surgeons, current president-elect of the International Nitric Oxide Society, and a current member of the Surgery, Anesthesia, Trauma NIH Study Section. In addition, he sits on the Scientific Advisory Board of four companies, has published over 300 manuscripts, and edited three books. Mitchell P. Fink, MD, Advisory board member, consultant and co-founder, is currently the President and CEO of Lycera Corporation, an pharmaceutical company developing first-in-class drugs to treat immune disorders and cancer. Previously, he was a founder of Logical Therapeutics. Prior to founding Logical Therapeutics, Dr. Fink was the Founding Chairman of the Department of Critical Care Medicine at the University of Pittsburgh School of Medicine. Dr. Fink is also the Watson Professor of Surgery at the University of Pittsburgh and past President of the Shock Society. He is a renowned expert in the field of critical care medicine and the management of trauma and sepsis. Previously, he was also a co-founder of Critical Therapeutics, Inc. (CRTX). Prior to that, Dr. Fink was the Johnson & Johnson Professor of Surgery at Harvard Medical School. Dr. Fink serves or has served as a senior consultant or Scientific Advisory Board member for numerous pharmaceutical or biotechnology companies, including Eli Lilly, Centocor (a Johnson & Johnson company), Ortho Biotech (another Johnson & Johnson company), Chiron, NovoNordisk and Somatogen. He has assisted several of these companies in making presentations to the Food and Drug Administration, and also has played a key role in the design of Phase I, II and III clinical trials. Dr. Fink received his medical degree from the Washington University School of Medicine, St. Louis, Missouri, and then completed his internship and residency in surgery at the Bethesda Naval Hospital in Maryland. Yoram Vodovotz, Ph.D., Advisory board member, consultant and co-founder, rounds out the team of Immunetrics inventors. Yoram received his Ph.D. in immunology at Cornell University Weill Graduate School of Medical Sciences, carried out two postdoctoral fellowships at the National Cancer Institute, and was subsequently the Director of Cellular and Molecular Research at the nonprofit Cardiovascular Research Institute at Washington Hospital Center. Currently, Yoram is Associate Professor of Surgery at the University of Pittsburgh, where he is continuing his research interests on nitric oxide and inflammation in sepsis, hemorrhagic shock, cancer, and vascular biology. © 2009 Immunetrics

Leadership

Immunetrics is staffed by a team of carefully trained Ph.D.-level biologists and mathematical modelers under the leadership of:

Steven Chang, M.S., CEO, board member, is a successful technology entrepreneur with more than 18 years of experience in developing complex computer models, optimization algorithms, and data mining systems. He was the founding Chairman of the board of directors for SCAI (Society for Complexity in Acute Illnesses). As founding CEO of Futuristics Labs, Steve raised two rounds of financing totaling over $10 million. Futuristics' proprietary technologies enabled real-time ad hoc query processing on terabyte sized databases with no loss in data resolution. Prior to founding Futuristics, Steve headed up the Intelligent Software Systems group at Westinghouse/CBS Corporation's Science and Technology Center and developed decision optimization and computer modeling systems that were successfully deployed in many Fortune 500 companies, including Kraft Foods, Colgate-Palmolive, Nestle, and Airborne Express. He was also instrumental in establishing the first Westinghouse presence on the Internet and was the recipient of two George Westinghouse Signature Awards for Excellence. Steve attained both BS and MS degrees in Electrical Engineering from the Rensselaer Polytechnic Institute.

John Bartels, senior software architect, has been developing mathematical models for 10 years, primarily in biological applications. John provides the technical direction and foundation for Immunetrics' custom simulation platforms and proprietary tools. Prior to joining Immunetrics, John held senior engineering positions at Nomos Corporation, Westinghouse Electric Corporation, and Digital Equipment Corporation. John holds a BS in Computer Science from the Rensselaer Polytechnic Institute.

Pat Rogan Patricia Rogan, Vice President, Operations, has more than twenty years of experience in executive financial and administrative management at public, private and startup technology companies, including software and biotechnology firms. Prior to joining Immunetrics, Pat was an executive at Innovation Works, Inc., a regional seed stage investor in technology companies. She previously held executive management positions at LaunchCyte, LLC and Dravo Corporation. Pat holds a B.A. and an MBA from the University of Pittsburgh.

Timothy Billiar Timothy R. Billiar, MD , Advisory board member, consultant and co-founder, is the George Vance Foster Professor and Chair of the Department of Surgery at the University of Pittsburgh. Tim received his M.D. degree from the University of Chicago, Pritzker School of Medicine in 1983, and then completed surgical training at the University of Minnesota and the University of Pittsburgh. This included a research fellowship under the guidance of Dr. Richard L. Simmons. Dr. Billiar is a trauma surgeon and critical care physician with a longstanding interest in inflammation and organ dysfunction. His laboratory was the first to clone the human inducible nitric oxide synthase and characterize its expression and function in a number of inflammatory settings. His laboratory also investigates hepatic responses in sepsis, hemorrhagic shock and ischemia reperfusion as well as aspects of acute vascular injury. He is currently funded by two program project grants, two RO1s, and is co-director of a trauma training grant. He is a past president of the Society of University Surgeons, current president-elect of the International Nitric Oxide Society, and a current member of the Surgery, Anesthesia, Trauma NIH Study Section. In addition, he sits on the Scientific Advisory Board of four companies, has published over 300 manuscripts, and edited three books.

Mitchell Fink Mitchell P. Fink, MD, Advisory board member, consultant and co-founder, is currently the President and CEO of Lycera Corporation, an pharmaceutical company developing first-in-class drugs to treat immune disorders and cancer. Previously, he was a founder of Logical Therapeutics. Prior to founding Logical Therapeutics, Dr. Fink was the Founding Chairman of the Department of Critical Care Medicine at the University of Pittsburgh School of Medicine. Dr. Fink is also the Watson Professor of Surgery at the University of Pittsburgh and past President of the Shock Society. He is a renowned expert in the field of critical care medicine and the management of trauma and sepsis. Previously, he was also a co-founder of Critical Therapeutics, Inc. (CRTX). Prior to that, Dr. Fink was the Johnson & Johnson Professor of Surgery at Harvard Medical School. Dr. Fink serves or has served as a senior consultant or Scientific Advisory Board member for numerous pharmaceutical or biotechnology companies, including Eli Lilly, Centocor (a Johnson & Johnson company), Ortho Biotech (another Johnson & Johnson company), Chiron, NovoNordisk and Somatogen. He has assisted several of these companies in making presentations to the Food and Drug Administration, and also has played a key role in the design of Phase I, II and III clinical trials. Dr. Fink received his medical degree from the Washington University School of Medicine, St. Louis, Missouri, and then completed his internship and residency in surgery at the Bethesda Naval Hospital in Maryland.

Yoram Vodovotz, Ph.D., Advisory board member, consultant and co-founder, rounds out the team of Immunetrics inventors. Yoram received his Ph.D. in immunology at Cornell University Weill Graduate School of Medical Sciences, carried out two postdoctoral fellowships at the National Cancer Institute, and was subsequently the Director of Cellular and Molecular Research at the nonprofit Cardiovascular Research Institute at Washington Hospital Center. Currently, Yoram is Associate Professor of Surgery at the University of Pittsburgh, where he is continuing his research interests on nitric oxide and inflammation in sepsis, hemorrhagic shock, cancer, and vascular biology.